445 related articles for article (PubMed ID: 24838514)
1. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
2. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.
Lee P; Murphy B; Miller R; Menon V; Banik NL; Giglio P; Lindhorst SM; Varma AK; Vandergrift WA; Patel SJ; Das A
Anticancer Res; 2015 Feb; 35(2):615-25. PubMed ID: 25667438
[TBL] [Abstract][Full Text] [Related]
6. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic.
Shabason JE; Tofilon PJ; Camphausen K
J Cell Mol Med; 2011 Dec; 15(12):2735-44. PubMed ID: 21362133
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics and histone deacetylase inhibitors.
Goey AK; Sissung TM; Peer CJ; Figg WD
Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
[TBL] [Abstract][Full Text] [Related]
8. Quisinostat is a brain-penetrant radiosensitizer in glioblastoma.
Lo Cascio C; Margaryan T; Luna-Melendez E; McNamara JB; White CI; Knight W; Ganta S; Opachich Z; Cantoni C; Yoo W; Sanai N; Tovmasyan A; Mehta S
JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37991020
[TBL] [Abstract][Full Text] [Related]
9. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
12. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Khan O; La Thangue NB
Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: a review on class-I specific inhibition.
Behera J; Jayaprakash V; Sinha BN
Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
[TBL] [Abstract][Full Text] [Related]
16. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
18. Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma.
Kang DW; Hwang WC; Noh YN; Kang Y; Jang Y; Kim JA; Min DS
J Cell Physiol; 2021 Jan; 236(1):549-560. PubMed ID: 32869317
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
20. Anticancer properties of chimeric HDAC and kinase inhibitors.
Biersack B; Polat S; Höpfner M
Semin Cancer Biol; 2022 Aug; 83():472-486. PubMed ID: 33189849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
